-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] With the changes in the competitive environment of the entire pharmaceutical market and the impact of generic drug competition, personnel changes in multinational companies have become more frequent
.
In the past August, news came that the executives of many multinational pharmaceutical companies, including AstraZeneca and Yang Sheng, had changed
.
On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca’s oncology business.
Chen Kangwei, general manager of the department, reported that it will take effect on August 30
.
On August 24, Sandoz announced to employees that Yu Huiming, President of Sandoz Greater China, will leave Sandoz to seek external career development opportunities.
The last working day is September 28, 2022
.
It is reported that Yu Huiming joined Sandoz as the general manager of Hong Kong in 2012, was appointed as the chief operating officer of Greater China in May of the same year, and officially served as the president of Sandoz Greater China at the beginning of this year
.
On August 19, Fresenius Group announced that Michael Sen will succeed Stephan Sturm as the new CEO of Fresenius Group on October 1, 2022
.
It is reported that Stephan Sturm has joined the Fresenius Group Management Committee since 2005.
He first served as the Chief Financial Officer of the Fresenius Group and was appointed as the CEO of the Fresenius Group on July 1, 2016
.
In addition to this personnel change, Fresenius Kabi has also promoted two business division heads.
Chen Guang, head of the Parenteral Nutrition and Anesthesia Division, was promoted to Executive Deputy General Manager of Fresenius Kabi Huarui Pharmaceuticals.
Shen Minyue, head of the General Business Division, was promoted to general manager of Beijing Fresenius Kabi Pharmaceutical Co.
,
Ltd.
In addition to the above-mentioned companies, in August, there were news of the resignation or the appointment of new employees by senior executives of multinational pharmaceutical companies such as Johnson & Johnson's executive vice president of R&D Mathhai Mammen, the compliance officer of the Janssen China Medical Compliance Department, and the CEO of Philips
.
While these executives are changing, from the perspective of whereabouts and experience, it seems that a war for talent is being staged among pharmaceutical companies
.
For example, Liu Ming, the new vice president of AstraZeneca in China, from the perspective of his resume, he used to be the vice president of Novartis Oncology and the head of the solid tumor business unit, responsible for breast cancer, lung cancer, melanoma, rare neuroendocrine tumors Zhu Jiakang, the former vice president of AstraZeneca China and the head of the lung cancer targeted therapy and tumor immunotherapy related fields, who resigned on June 9 this year, was announced to join Novartis in July as Novartis’ innovative drug China Oncology Head of Therapeutic Area and a member of the Innovative Medicines China management team, reporting to Zhang Ying, President and Managing Director of Novartis Innovative Medicines China, effective July 12
.
The industry pointed out that with the fierce competition in the research and development of innovative drugs, the demand for talents from related pharmaceutical companies has become more and more intense.
In particular, compound talents with cross-border backgrounds and emerging technologies will be favored
.
It is worth mentioning that, in addition to changing among foreign pharmaceutical companies, the executives of multinational pharmaceutical companies have also flowed to local pharmaceutical companies
.
For example, on April 1 this year, Zhou You, the former chief marketing officer of Sanofi China, joined CStone Pharmaceuticals; on March 31, Wu Kun, the former head of Pfizer Biopharmaceutical Group China and head of Pfizer Innovative Medical China, assumed his duties as Ji Xing Pharmaceuticals; also in March, Zai Lab announced the appointment of Josh Smiley, who was responsible for finance, corporate strategy, business development, venture capital and global business service operations at Eli Lilly, as chief operating officer.
The industry believes that in the future, China's local innovative biopharmaceuticals will usher in new opportunities for development, enter explosive growth, or be the main reason for attracting talent from multinational pharmaceutical companies
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
.
In the past August, news came that the executives of many multinational pharmaceutical companies, including AstraZeneca and Yang Sheng, had changed
.
On August 30, AstraZeneca announced the appointment of Liu Ming as Vice President of AstraZeneca China, Head of the Lung Cancer Treatment and Tumor Immunotherapy-related Business Units of the Oncology Division, and joined the Chinese management team to directly report to AstraZeneca’s oncology business.
Chen Kangwei, general manager of the department, reported that it will take effect on August 30
.
On August 24, Sandoz announced to employees that Yu Huiming, President of Sandoz Greater China, will leave Sandoz to seek external career development opportunities.
The last working day is September 28, 2022
.
It is reported that Yu Huiming joined Sandoz as the general manager of Hong Kong in 2012, was appointed as the chief operating officer of Greater China in May of the same year, and officially served as the president of Sandoz Greater China at the beginning of this year
.
On August 19, Fresenius Group announced that Michael Sen will succeed Stephan Sturm as the new CEO of Fresenius Group on October 1, 2022
.
It is reported that Stephan Sturm has joined the Fresenius Group Management Committee since 2005.
He first served as the Chief Financial Officer of the Fresenius Group and was appointed as the CEO of the Fresenius Group on July 1, 2016
.
In addition to this personnel change, Fresenius Kabi has also promoted two business division heads.
Chen Guang, head of the Parenteral Nutrition and Anesthesia Division, was promoted to Executive Deputy General Manager of Fresenius Kabi Huarui Pharmaceuticals.
Shen Minyue, head of the General Business Division, was promoted to general manager of Beijing Fresenius Kabi Pharmaceutical Co.
,
Ltd.
In addition to the above-mentioned companies, in August, there were news of the resignation or the appointment of new employees by senior executives of multinational pharmaceutical companies such as Johnson & Johnson's executive vice president of R&D Mathhai Mammen, the compliance officer of the Janssen China Medical Compliance Department, and the CEO of Philips
.
While these executives are changing, from the perspective of whereabouts and experience, it seems that a war for talent is being staged among pharmaceutical companies
.
For example, Liu Ming, the new vice president of AstraZeneca in China, from the perspective of his resume, he used to be the vice president of Novartis Oncology and the head of the solid tumor business unit, responsible for breast cancer, lung cancer, melanoma, rare neuroendocrine tumors Zhu Jiakang, the former vice president of AstraZeneca China and the head of the lung cancer targeted therapy and tumor immunotherapy related fields, who resigned on June 9 this year, was announced to join Novartis in July as Novartis’ innovative drug China Oncology Head of Therapeutic Area and a member of the Innovative Medicines China management team, reporting to Zhang Ying, President and Managing Director of Novartis Innovative Medicines China, effective July 12
.
The industry pointed out that with the fierce competition in the research and development of innovative drugs, the demand for talents from related pharmaceutical companies has become more and more intense.
In particular, compound talents with cross-border backgrounds and emerging technologies will be favored
.
It is worth mentioning that, in addition to changing among foreign pharmaceutical companies, the executives of multinational pharmaceutical companies have also flowed to local pharmaceutical companies
.
For example, on April 1 this year, Zhou You, the former chief marketing officer of Sanofi China, joined CStone Pharmaceuticals; on March 31, Wu Kun, the former head of Pfizer Biopharmaceutical Group China and head of Pfizer Innovative Medical China, assumed his duties as Ji Xing Pharmaceuticals; also in March, Zai Lab announced the appointment of Josh Smiley, who was responsible for finance, corporate strategy, business development, venture capital and global business service operations at Eli Lilly, as chief operating officer.
The industry believes that in the future, China's local innovative biopharmaceuticals will usher in new opportunities for development, enter explosive growth, or be the main reason for attracting talent from multinational pharmaceutical companies
.
Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to anyone
.
